

In the Claims

Please substitute the following claims 12, 16 and 17 for claims 12, 16 and 17 now pending in the above-identified application.

Please cancel claims 18-20.

Claims 1-11 (Cancelled)

12. (Currently Amended) A method of retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer in a mammal in need thereof, comprising administering to said mammal:

- (i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C₂H₅ (SEQ ID NO.: 2) or a salt thereof and cyproterone acetate, in combination with
- (ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase ~~activity~~. activity;

wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

13. (Previously Presented) The method according to claim 12, wherein said hormonal agent is 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C₂H₅ (SEQ ID NO.: 2) or an acetate thereof.

14. (Previously Presented) The method according to claim 12, wherein said hormone-dependent cancer is prostatic cancer, ovarian cancer, cervical cancer or breast cancer.

15. (Previously Presented) The method according to claim 12, wherein said tyrosine kinase inhibitor is PD153035.

16. (Currently Amended) A method of treating ~~or preventing~~ cancer in a mammal in need thereof by retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer, comprising administering

- (i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C₂H₅ (SEQ ID NO.: 2) or a salt thereof, and cyproterone acetate in combination with
- (ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase ~~activity-~~ activity;

wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

17. (Currently Amended) A method of suppressing the metastasis or recurrence of a cancer by retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer, in a mammal in need thereof, comprising administering

- (i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro NH-C₂H₅ (SEQ ID NO.: 2) or a salt thereof, and cyproterone acetate in combination with

(ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase ~~activity.~~ activity;

wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

Claims 18-20. (Cancelled)